Therapy of Hypoparathyroidism by Replacement with Parathyroid Hormone

Table 1

Pharmacokinetic and -dynamic characteristics of recombinant human intact parathyroid hormone (rhPTH_1--84) and teriparatide (rhPTH_1--34) following a subcutaneous injection into the abdominal skin [32].

	PTH analogue
	rhPTH1--34	rhPTH1--84
Bioavailability (%)	95%	55%
Time to peak PTH level (hours)	0.5 h	1-2 h
Plasma half-life (hours)	1.0 h	1.5 h
Time to peak plasma calcium levels (hours)	4–6 h	6–8 h

The data in the table are derived from EMEA online (http://www.ema.europa.eu/ema/). EMA Preotact product description and EMA Forsteo product description.